709 Phase II Study to assess the safety and efficacy of the CLEVER-1 antibody bexmarilimab in combination with PD-1 blockade in patients with advanced solid tumors – BEXCOMBO
Author:
Bono Petri,Jalkanen Juho,Pawlitzky Inka,Fjaellskog Marie-Louise,Ahlin Cecilia
Publisher
BMJ Publishing Group Ltd